骨髓间充质干细胞治疗肝脏疾病研究进展

doi:10.3969/j.issn.1672-5069.2015.02.032

Abstract

Abstract: Bone marrow mesenchymal stem cells （BMSCs） can be differentiated into functional and mature hepatocytes in the proper conditions. The application of BMSCs may provides a new approach for end-stage liver disease. In this review,we summarized the progress in the application of BMSCs for treating patients with liver diseases such as cirrhosis,hepatocellular carcinoma （HCC） and liver failure. We’ll also discuss the transplantation and the existing problems in the practice.

Key words: Bone marrow mesenchymal stem cells, Cirrhosis, Hepatocellular carcinoma, Liver failure, Transplantation

Jiang Hua, Gao Jianpeng. Progress in bone marrow mesenchymal stem cells in the treatment of patients with liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(2): 217-220.

References

[1] Kim W,Kremers WK. Benefits of “the benefit model” in liver transplantation. Hepatology,2008,48（3）:697-698.
[2] Friedenstein A,Chailakhyan R,Gerasimov U. Bone marrow osteogenic stem cells:in vitro cultivation and transplantation in diffusion chambers,Cell Prolif,1987,20（3）:263-272.
[3] Chen YX,Weng ZH,Zhang SL. Notch3 regulates the activation of hepatic stellate cells. World J gastroenterol,2012,18（12）:1397-1403.
[4] Seki N,Toh U,Kawaguchi K,et al. Tricin inhibits proliferation of human hepatic stellate cells in vitro by blocking tyrosine phosphorylation of PDGF receptor and its signaling pathways. J Cell Biochem,2012,113（7）:2346-2355.
[5] Tomita K,Tamiya G,Ando S,et al. Tumour necrosis factor α signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut,2006,55（3）:415-424.
[6] 杨文,覃山羽,姜海行,等. 骨髓间充质干细胞体外调控肝星状细胞死亡受体 5 的表达. 中国组织工程研究,2012,16（27）:4947-4952.
[7] Lin H,Xu R,Zhang Z,et al. Implications of the immunoregulatory functions of mesenchymal stem cells in the treatment of human liver diseases. Cell Mol Immunol,2010,8（1）:19-22.
[8] Wang Pp,Xie Dy,Liang XJ,et al. HGF and direct mesenchymal stem cells contact synergize to inhibit hepatic stellate cells activation through TLR4/NF-kB pathway. PloS One,2012,7（8）:e43408.
[9] Sánchez PL,San Román JA,Villa A,et al. Contemplating the bright future of stem cell therapy for cardiovascular disease. Nat Clin Pract Cardiovasc Med,2006,Suppl 1（3）:S138-S151.
[10] Alison M,Islam S,Lim S. Stem cells in liver regeneration,fibrosis and cancer: the good,the bad and the ugly. J Pathol,2009,217（2）:282-298.
[11] Pai M,Zacharoulis D,Milicevic MN,et al. Autologous infusion of expanded mobilized adult bone marrow-derived CD34&plus; cells into patients with alcoholic liver cirrhosis.Am J Gastroenterol,2008,103（8）:1952-1958.
[12] Kharaziha P,Hellstrom PM,Noorinayer B,et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection:a phase I-II clinical trial. Eur J Gastroenterol Hepatol,2009,21（10）:1199-1205.
[13] Mohsin S,Shams S,Ali Nasir G,et al. Enhanced hepatic differentiation of mesenchymal stem cells after pretreatment with injured liver tissue. Differentiation,2011,81（1）:42-48.
[14] 欧阳石,刘树人,程涛,等. 自体骨髓间充质干细胞肝动脉移植治疗失代偿期肝硬化. 中国组织工程研究,2013,17（36）:6455-6461.
[15] 陈双庆,王培军,李铭华,等. 磁标记骨髓间充质干细胞对肝细胞癌的抑制作用. 临床放射学杂志,2009,28（10）:1454-1458.
[16] Roshdy NK,Rashed LA,Sabry D,et al. Efficacy of mesenchymal stem cells in suppression of hepatocarcinorigenesis in rats: possible role of Wnt signaling.Journal of experimental & clinical cancer research. J Exp Clin Cancer Res,2011,30:49.
[17] Xie C,Xie D,Lin B,et al. Interferon-β gene-modified human bone marrow mesenchymal stem cells attenuate hepatocellular carcinoma through inhibiting AKT/FOXO3a pathway. Br J Cancer,2013,109（5）:1198-1205.
[18] Gao Y,Yao A,Zhang W,et al. Human mesenchymal stem cells overexpressing pigment epithelium-derived factor inhibit hepatocellular carcinoma in nude mice. Oncogene,2010,29（19）:2784-2794.
[19] 李兰娟. 肝衰竭诊疗指南. 中华内科杂志,2006,45（12）:1053.
[20] Hang HL,Xia Q. Role of BMSCs in liver regeneration and metastasis after hepatectomy.World J gastroenterol,2014,20（1）:126.
[21] Milwid JM,Ichimura T,Li M,et al. Secreted factors from bone marrow stromal cells upregulate IL-10 and reverse acute kidney injury. Stem Cells Int,2012,2012：392050.
[22] Zhou RR,Zhao SS,Zou MX,et al. HMGB1 cytoplasmic translocation in patients with acute liver failure. BMC gastroenterol, 2011,11（1）:21.
[23] 刘婷, 贺永文. 高迁移率族蛋白 B1 在急性肝功能衰竭小鼠中的表达变化. 中华传染病杂志,2010,4（28）:209-213.
[24] Campard D,Lysy PA,Najimi M,et al. Native umbilical cord matrix stem cells express hepatic markers and differentiate into hepatocyte-like cells. Gastroenterology,2008,134（3）:833-848.
[25] 易珍,孙水林,刘翠云,等. 同种异体骨髓间充质干细胞对急性肝衰竭 HMGB1 的影响. 世界华人消化杂志,2012,20（16）:1396-1401.
[26] Ikeda H,Kume Y,Tejima K,et al. Rho-kinase inhibitor prevents hepatocyte damage in acute liver injury induced by carbon tetrachloride in rats.Am J Physiol Gastrointest Liver Physiol,2007,293（4）:G911-G917.
[27] Thorlacius K,Slotta JE,Laschke MW,et al. Protective effect of fasudil,a Rho-kinase inhibitor,on chemokine expression,leukocyte recruitment,and hepatocellular apoptosis in septic liver injury. J Leukoc Biol,2006,79（5）:923-931.
[28] 顾劲扬,施晓雷,袁献温,等. 骨髓间充质干细胞诱导肝细胞耐受肝功能衰竭血清细胞毒性的研究. 中华实验外科杂志,2014,31（002）:308-311.
[29] Peng L,Xie Dy,Lin BL,et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B:Short-term and long-term outcomes. Hepatology,2011,54（3）:820-828.
[30] Cai J,Zhang X,Wang X,et al. In vivo MR imaging of magnetically labeled mesenchymal stem cells transplanted into rat liver through hepatic arterial injection. Contrast Media Mol Im,2008,3（2）:72-77.
[31] Mohamadnejad M,Namiri M,Bagheri M,et al. Phase 1 human trial of autologous bone marrow-hematopoietic stem cell transplantation in patients with decompensated cirrhosis. World J Gastroenterol,2007,13（24）:3359.
[32] 何秀华,李东良,江军,等. 移植途径对大鼠骨髓间充质干细胞归巢及肝功能恢复的影响. 中华细胞与干细胞杂志（电子版）,2012,1（1）:37-40.
[33] Di Bonzo LV,Ferrero I,Cravanzola C,et al. Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine:engraftment and hepatocyte differentiation versus profibrogenic potential. Gut,2008,57（2）:223-231.
[34] Schrepfer S,Deuse T,Reichenspurner H,et al. Stem cell transplantation:the lung barrier. Transplant Pro,2007,2（39）:573-576.

Progress in bone marrow mesenchymal stem cells in the treatment of patients with liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Gao Lei, Cao Lei, Wang Ruifang, et al.. Protective effect of human umbilical cord mesenchymal stem cell transplantation on alcoholic liver injury in rats [J]. Journal of Practical Hepatology, 2019, 22(6): 812-815.
[3]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[4]	Zhu Yage, Liu Jinfeng.. Therapeutic efficacy of adenosine methionine and glycyrrhizin combination in treatment of patients with alcoholic cirrhosis and its effect on serum BGP levels [J]. Journal of Practical Hepatology, 2019, 22(6): 872-875.
[5]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[6]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[7]	Liu Li, Yang Lie, Chen Haiyang, et al.. Changes of hemodynamics after splenectomy combined with pericardial devascularization in patients with cirrhotic portal hypertention complicated by splenic artery steal syndrome [J]. Journal of Practical Hepatology, 2019, 22(6): 884-887.
[8]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[9]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[10]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[11]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[12]	Song Haiyan, Chen Xi, Zhang Junfei, et al. Application of vorionazole in the treatment of patients with liver failure complicated by pulmonary fungal infection [J]. Journal of Practical Hepatology, 2019, 22(5): 676-679.
[13]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.